HURA Company Profile and Key Details

TuHURA Biosciences, Inc. has 50.05 million shares outstanding. The public float is 30.47 million shares, elevated short interest at 7.30% of float. This equals 2.90 million shares. The short ratio is 4.18 days. Institutional investors hold 18.68% of the float. Insiders own 31.02%.

TuHURA Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.67. This means the shares are trading above this model’s fair value.

HURA has shown weak momentum, losing -4.82% over the past week and -71.63% over the past quarter, though year-to-date performance is down -10.03%. Short-term trend indicators are bullishly aligned (SMA20 27.38%, SMA50 -13.64%, SMA200 -64.46%). The stock’s 14-day RSI is 57.32 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -83.02% below its high and over 97.59% above its low. Average 10-day trading volume of 7.21 million shares is significantly above the 3-month average of 1.15 million, indicating heightened recent market interest.

TuHURA Biosciences, Inc. generated EPS of -$0.65 over the past year. Five-year average earnings growth is 76.02%. Wall Street analysts project EPS growth of 62.73% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $8.00. The high target offers 900.0% upside. The low target suggests 515.38% downside. The mean target is $9.15. This offers 603.85% upside. TuHURA Biosciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by -6.67%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include 84.86% in November 13, 2024.

TuHURA Biosciences, Inc. (NASDAQ:HURA) closed at $1.30 USD, gaining $0.49 (60.47%) from the previous close of $0.81. The stock is currently mid-range between its 52-week high and low $0.41 and $4.77. With a market capitalization of about $73.42 million, TuHURA Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.12). Key stats such as the average daily volume over the past year has been around 870.02 thousand shares, trading with heavier-than-usual volume. Headquartered in Tampa, None, TuHURA Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James A. Bianco, the company employs approximately 19 people and listed since February 22, 2013. TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.

TuHURA Biosciences, Inc. (NASDAQ:HURA) shares are down -10.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows TuHURA Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.98. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.29, suggesting 614.62% upside. Our AI forecast model points to short-term weakness (-56.92% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-99.23% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that TuHURA Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -56.92%, with price expected at $0.56 by February 23, 2026, within a range of $0.51 to $0.61 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 08, 2026, with a range of $0.00 to $5.47. 1-Year Outlook: Projected loss of -99.23%, with price at $0.01 by February 09, 2027, within a range of $0.00 to $135.88.

TuHURA Biosciences, Inc. trades at a P/E ratio of -0.98, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.96 suggesting the stock is closer to book value. The P/FCF stands at -4.67, also below market averages.